ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO865

Mitochondrial DNA Haplotypes and Risk of CKD and AKI

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention


  • Jotwani, Vasantha, University of California San Francisco, San Francisco, California, United States
  • Sarnak, Mark J., Tufts University, Medford, Massachusetts, United States
  • Thiessen Philbrook, Heather, Johns Hopkins University, Baltimore, Maryland, United States
  • Katz, Ronit, University of Washington, Seattle, Washington, United States
  • Ix, Joachim H., University of California San Diego, La Jolla, California, United States
  • Waikar, Sushrut S., Boston University, Boston, Massachusetts, United States
  • Parikh, Chirag R., Johns Hopkins University, Baltimore, Maryland, United States
  • Tranah, Gregory J., California Pacific Medical Center, San Francisco, California, United States
  • Parikh, Samir M., The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Shlipak, Michael, University of California San Francisco, San Francisco, California, United States
  • Arking, Dan, Johns Hopkins University, Baltimore, Maryland, United States

Experimental models suggest an important role for mitochondrial dysfunction in the pathogenesis of chronic kidney disease (CKD) and acute kidney injury (AKI), but little is known regarding the impact of mitochondrial genetic variation on kidney health. We evaluated associations of inherited mitochondrial DNA (mtDNA) haplotypes with risk of CKD and AKI in a large population-based cohort.


Among UK Biobank participants who self-identified as white, we tested eight distinct mtDNA haplotypes (N=379,432) with minor allele frequency >0.5% that were previously identified based on associations with traits associated with mtDNA copy number. Individuals with prevalent end-stage kidney disease were excluded. We used linear and logistic regression models to evaluate associations of these mtDNA haplotypes with estimated glomerular filtration rate by serum creatinine and cystatin C (eGFR, N=362,802), AKI defined by diagnostic codes (N=14,170 cases), and urine albumin/creatinine ratio (ACR, N=114,662).


The mean age was 57±8 years and the mean eGFR was 90±14 ml/min/1.73m2. MtDNA haplotype was significantly associated with eGFR (p= 2.84E-12), but not with risk of AKI (p=0.256) or urine ACR (p=0.538). The association of mtDNA haplotype with eGFR remained significant after adjustment for diabetes mellitus and hypertension (p=1.20E-10). When compared to the reference haplotype, mtDNA haplotypes I, IV, and V were each associated with higher eGFR (Table).


Among self-identified white UK Biobank participants, mtDNA haplotype was associated with eGFR, but not with AKI risk or albuminuria.


  • NIDDK Support